PRT3789, a First-in-Class Intravenous SMARCA2 Degrader, in Advanced Solid Tumors With a SMARCA4 Mutation: Phase 1 Trial

Timothy A. Yap, Afshin Dowlati, Ibiayi Dagogo-Jack, Julien Vibert, Alexander I. Spira, Victor Moreno, Salman R. Punekar, Emiliano Calvo, Guru P. Sonpavde, Mark Awad, Jonathan W. Riess, Tatiana Hernández-Guerrero, Benjamin Herzberg, Antoine Italiano, Aurelie Swalduz, Ticiana A Leal, Patricia LoRusso, Egbert F. Smit, Edward B. Garon, William Novotny, Robin Guo